Abionic SA
Edit

Abionic SA

http://www.abionic.com/
Last activity: 19.06.2026
Active
Categories: BioTechDiagnosticsHealthTechITMedTechPersonalProductSupplyTechnologyTools
Abionic SA is positioned at the boundaries of medical technology, biotechnology & nanotechnology and is developing a novel diagnostic tool that will provide patients with personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.
Mentions
69
Location: Switzerland, Vaud, Epalinges
Total raised: $24.94M

Investors 6

Funding Rounds 2

DateSeriesAmountInvestors
29.03.2018Series C$20.91M-
15.10.2014Series B$4.03M-

Mentions in press and media 69

DateTitleDescription
19.06.2026Swiss biotechs display their innovations at BIO 2026 in San Diego The BIO International Convention attracts over 1,600 exhibitors and 21,000 attendees who network intensively over 4 days, discover new opportunities and promising partnerships. The attendees benefit from a broad spectrum of life sciences a...
07.10.2024FDA approvals and clinical advancements propel life sciences startups forward Alentis Therapeutics, a clinical-stage biotech company focused on developing treatments for cancer and fibrosis, has received FDA clearance for an Investigational New Drug (IND) application for ALE.P02, a novel anti-CLDN1 ADC targeting squ...
22.02.2024Startups welcome field experts in C-level roles After more than a decade of building and leading Abionic, the developer of nanofluidic point-of-care diagnostic solutions for sepsis diagnostics, the company’s founder, Nicolas Durand, handed over his CEO role to Patrick Pestalozzi, who wi...
13.06.2023The Swiss Medtech Award 2023 goes to Abionic
10.08.2022Abionic receives IVDR certification for its ultra-rapid Sepsis test
30.04.2021Clinical trial confirms Abionic’s ability to detect Sepsis earlier
30.04.2021Clinical trial confirms Abionic’s ability to detect Sepsis earlierPublished recently in the Critical Care Journal, the study was designed to establish performance characteristics of the PSP test in the early detection of sepsis. A total of 300 adult ICU patients at high risk of developing sepsis admitted ...
26.11.2020Abionic launches new tool for faster triage of Covid19 patientsSince the outbreak of the Covid-19 pandemic, countries around the globe have seen increasing occupancy rates in hospitals, particularly in ICUs, and many ICUs are at or near full capacity. Patient triage, until now, has relied mostly on pat...
26.11.2020Abionic launches new tool for faster triage of Covid19 patients
20.06.2020Rising out of the crisis: Where to find new markets and customersThe pandemic has upended the business models of most startups and existing companies. As the economy reopens, companies are finding that customers may have disappeared or that their spending behavior has changed. Suppliers are going out of ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In